The irony of hepatotoxicity with elevated ALT levels in a drug designed to help the liver is not lost on me…the paucity of any meaningful side affects with Leronlimab is a big reason why I invested. There is always a risk/benefit calculation made in taking any drug. While Leronlimab will be paired with Resmetirom in the mouse study, I hope they have Leronlimab alone in one study arm. Stellar success in a Leronlimab only arm would prompt BP discussions that transcend partnership. Madrigal would be rightly concerned about losing their golden goose if it is found our goose lays platinum eggs.